Screener
Castle Biosciences CSTL Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| NET REVENUES | $83,679 | $87,988 |
| OPERATING EXPENSES | ||
| Cost of sales (exclusive of amortization of acquired intangible assets) | 20,533 | 16,383 |
| Research and development | 14,428 | 12,588 |
| Selling, general and administrative | 64,899 | 58,620 |
| Amortization of acquired intangible assets | 2,226 | 28,325 |
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's total cost of revenue?
- Castle Biosciences (CSTL) reported total cost of revenue of $20.53M in Q1 2026.
- How has Castle Biosciences's total cost of revenue changed year-over-year?
- Castle Biosciences's total cost of revenue increased by 25.3% year-over-year, from $16.38M to $20.53M.
- What is the long-term trend for Castle Biosciences's total cost of revenue?
- Over 4 years (2021 to 2025), Castle Biosciences's total cost of revenue has grown at a 45.6% compound annual growth rate (CAGR), from $15.82M to $71.03M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Castle Biosciences's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude